&Partners Has $955,000 Stock Position in Bristol-Myers Squibb (NYSE:BMY)

&Partners lifted its holdings in shares of Bristol-Myers Squibb (NYSE:BMYFree Report) by 76.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,611 shares of the biopharmaceutical company’s stock after purchasing an additional 7,616 shares during the period. &Partners’ holdings in Bristol-Myers Squibb were worth $955,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Clearbridge Investments LLC boosted its holdings in shares of Bristol-Myers Squibb by 0.4% during the 3rd quarter. Clearbridge Investments LLC now owns 112,446 shares of the biopharmaceutical company’s stock worth $6,526,000 after buying an additional 459 shares in the last quarter. LPL Financial LLC boosted its stake in Bristol-Myers Squibb by 4.6% during the third quarter. LPL Financial LLC now owns 2,026,052 shares of the biopharmaceutical company’s stock worth $117,592,000 after acquiring an additional 88,447 shares in the last quarter. Gallacher Capital Management LLC acquired a new stake in Bristol-Myers Squibb in the third quarter worth $290,000. Syntax Advisors LLC raised its holdings in shares of Bristol-Myers Squibb by 7.3% during the third quarter. Syntax Advisors LLC now owns 3,808 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 258 shares during the period. Finally, Socorro Asset Management LP boosted its position in shares of Bristol-Myers Squibb by 9.3% during the 3rd quarter. Socorro Asset Management LP now owns 144,519 shares of the biopharmaceutical company’s stock worth $8,388,000 after purchasing an additional 12,291 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on BMY. Barclays dropped their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Wells Fargo & Company increased their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 17th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Finally, BMO Capital Markets reduced their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $60.00.

Get Our Latest Research Report on Bristol-Myers Squibb

Bristol-Myers Squibb Stock Performance

BMY stock traded up $0.89 during midday trading on Friday, hitting $41.93. The company’s stock had a trading volume of 35,830,690 shares, compared to its average volume of 13,967,854. Bristol-Myers Squibb has a 1 year low of $39.63 and a 1 year high of $65.85. The stock has a market cap of $85.00 billion, a price-to-earnings ratio of -13.53, a PEG ratio of 13.89 and a beta of 0.43. The stock’s 50-day moving average price is $43.60 and its 200 day moving average price is $48.43. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.05 earnings per share. On average, equities analysts forecast that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be paid a $0.60 dividend. The ex-dividend date is Friday, July 5th. This represents a $2.40 annualized dividend and a yield of 5.72%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Company Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Stories

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYFree Report).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.